Provexis surges on Crohn's disease trial

Provexis, the life-science business, has begun a clinical trial for its NSP#3G plantain medical food for Crohn's disease patients."With the trial now starting and combined with recently obtained healthy human data, the Company will now commence seeking to identify potential global license or co-development partners to address this substantial market opportunity," said the group.The group said it has completed the necessary pre-trial processes and will now begin a two-centre trial on Crohn's disease patients in remission on 18 August 2009. The trial will last for approximately 18 months, with 72 patients taking part."Our new technology addresses an important patient need for a debilitating disease where no effective medical food products for maintaining remission are available currently. Laboratory and human trial work to date has been very promising and we look forward to successful clinical data from this important trial," said chief executive Stephen Moon.